RBC Capital Rates Edgewise Therapeutics (EWTX) buy

RBC Capital maintains its buy rating on Edgewise Therapeutics with a $59 price target, a 51.94% upside from the current price.

By TradeTexts Research Desk · Published Jun 17, 2026, 12:02 PM EDT · Updated Jun 24, 2026, 7:02 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

RBC Capital rated Edgewise Therapeutics, Inc. ($EWTX) "buy" with a $59 price target on June 17, 2026.

Since the rating, $EWTX is up 21.5% after 1 week, up 14.2% after 1 month and up 6.8% to date (from the $34.82 close on Jun 17, 2026).

EWTX Edgewise Therapeutics, Inc.

$37.19 +56.59% year to date

Daily close · Oct 16, 2026

Key Points

RBC Capital reiterated its buy rating on Edgewise Therapeutics, Inc. (EWTX) with a price target of $59 on June 17, 2026.
RBC Capital's $59 price target implies 51.94% upside from Edgewise Therapeutics, Inc.'s ($EWTX) current $38.83 share price.
Edgewise Therapeutics, trading at $33.95, has a market cap of $3.65 billion and a 52-week high of $40.77.
Insiders recently bought shares, while analysts maintain a buy consensus with a mean target price of $46.08.

Get $EWTX trade alerts by text

We text you when insiders, Congress or big funds trade $EWTX. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Edgewise Therapeutics, Inc. alert may contain errors. Disclosures

RBC Capital reiterated its buy rating on Edgewise Therapeutics, Inc. (NasdaqGS: EWTX) on June 17, 2026, setting a price target of $59. Analyst Leonid Timashev maintained a positive outlook on the biopharmaceutical company, which focuses on therapies for muscle disorders.

Other Institutional Activity in Edgewise Therapeutics

ORBIMED ADVISORS LLC held steady with 15.52 million shares valued at about $488.8 million. RA CAPITAL MANAGEMENT, L.P. also maintained its position with 10.43 million shares worth $328.5 million. PARADIGM BIOCAPITAL ADVISORS LP increased its holdings by 823,828 shares to a total of 7.37 million shares, valued at $232 million. Meanwhile, BLACKROCK, INC. reduced its stake by 157,585 shares, ending with 6.47 million shares valued at $203.9 million. JANUS HENDERSON GROUP PLC added 1.35 million shares, bringing their total to 5.92 million shares worth $186.3 million.

Edgewise Therapeutics, Inc. Stock Down 14.3%

Shares of Edgewise Therapeutics traded at $33.95 on the NasdaqGS. The company has a market cap of approximately $3.65 billion. The stock's 52-week range is between $12.15 and $40.77, with a 50-day moving average of $33.68 and a 200-day moving average of $25.78. The company is not currently profitable, as indicated by its negative forward P/E ratio of -15.34. Its beta is 0.304, suggesting lower volatility compared to the market.

12-month forecast

$EWTX price target

Edgewise Therapeutics, Inc. daily closes and this analyst's $59 target. Not advice.

Insider Buying and Selling at Edgewise Therapeutics, Inc.

On June 5, 2026, several insiders bought shares in Edgewise Therapeutics. Jonathan Fox, Christopher Martin, and Badreddin Edris acquired 16,377, 16,377, and 8,188 shares respectively. Meanwhile, on May 5, 2026, CMO Joanne Donovan sold 50,000 shares at an average price of $38.57 and bought 50,000 shares at $7.08.

Analysts Set New Price Targets

On June 17, 2026, RBC Capital maintained its buy rating with a $59 target. Goldman Sachs also maintained a hold rating with a $32 target on the same day. On June 16, 2026, HC Wainwright & Co. reiterated a buy rating with a $45 target. Overall, the consensus among analysts is a buy, with an average target price of $46.08 based on 12 opinions.

About Edgewise Therapeutics

Edgewise Therapeutics, Inc. is a biopharmaceutical company based in Boulder, Colorado. It focuses on discovering and developing therapies for muscle disorders. The company's lead candidate, sevasemten, is in Phase II trials for treating dystrophinopathies like Duchenne and Becker muscular dystrophy. Edgewise is also working on EDG-7500 for cardiac disorders and EDG-15400 for heart failure. The company was founded in 2017 and is led by CEO Dr. Kevin Koch.

Bottom Line

RBC Capital's reiteration of a buy rating reflects continued confidence in Edgewise Therapeutics' potential. Investors track such analyst actions closely to gauge market sentiment. However, it's important to remember that these ratings are based on past data and do not predict future performance.